Deutsche Bank raised the firm’s price target on HealthEquity (HQY) to $120 from $117 and keeps a Buy rating on the shares following the Q3 report. The firm sees “multiple growth options” for the company.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity’s Strong Q3 Performance and Raised Guidance Justify Buy Rating with Significant Upside Potential
- Balanced Outlook for Healthequity Amid Strong Performance and Economic Uncertainty Justifies Hold Rating
- HealthEquity price target raised to $129 from $126 at JPMorgan
- HealthEquity’s Strategic Growth and Market Position Justify Buy Rating
- Healthequity’s Strong Performance and Growth Prospects Justify Buy Rating